Introduction to the Regulatory Update
According to a notification issued by Japan’s Ministry of Health, Labour and Welfare (MHLW) on February 27, 2026, the Q&A document on the formulation of pediatric drug development plans for drugs intended for adults has been revised. The revised Q&A will come into effect on May 1, 2026, replacing the previous version issued on March 29, 2024. The revision aims to clarify regulatory expectations and operational procedures related to pediatric development planning when companies are developing drugs primarily intended for adult populations.
Obligation Status of Pediatric Development Planning
The revised Q&A clarifies that preparing a pediatric drug development plan is not a strict legal obligation but a best-effort requirement. Pharmaceutical companies developing drugs intended for adults are expected to consider pediatric development and, when appropriate, make reasonable efforts to prepare a development plan.
However, this requirement does not apply to generic drugs developed with the same active ingredient, indication, and dosage as already approved products. On the other hand, if a product contains the same active ingredient but is being developed for new indications, companies should attempt to prepare a pediatric development plan.
Confirmation Procedures with PMDA
The revised Q&A provides clearer guidance on how sponsors can obtain confirmation of pediatric development plans from the Pharmaceuticals and Medical Devices Agency (PMDA). Several consultation pathways are available, including:
Sponsors may request confirmation of pediatric development plans during these consultations, provided that the relevant information is included in the consultation materials. In some cases, confirmation may also be obtained during the review process of the adult drug application.
Flexible Development Approaches Beyond Clinical Trials
The updated Q&A emphasizes that pediatric development plans do not necessarily require the conduct of new clinical trials. Alternative approaches such as:
may be used to support pediatric development strategies if they are scientifically appropriate to obtain approval.
Expected Timelines for Pediatric Development
Although the guidance does not define a uniform development timeline, it provides indicative expectations to ensure that pediatric development progresses without undue delay.
For drugs where a separate pediatric formulation is not required, companies are encouraged to:
If a pediatric-specific formulation is required, the expected timeframe may extend to approximately 3 years after adult approval before submitting a trial notification or initiating development activities.
Scope of Pediatric Populations and Development Strategy
The guidance states that pediatric development should consider all relevant age groups, including neonates, where appropriate. Sponsors may adopt a stepwise development approach, gradually expanding the target pediatric population while accounting for differences in body size, maturation, and dosing requirements.
If certain pediatric age groups are excluded from development, sponsors must provide a clear scientific rationale explaining why development is unnecessary.
Documentation in Regulatory Submissions
When a pediatric development plan has been confirmed through PMDA consultation, the confirmation should be documented in regulatory records. Specifically:
This documentation ensures regulatory transparency and traceability of the pediatric development strategy during the review process.
Conclusion
The revision of the Q&A clarifies Japan’s expectations for pediatric drug development planning during adult drug development programs. By defining consultation pathways, flexible evidence approaches, and indicative timelines, the update aims to encourage earlier consideration of pediatric use while maintaining development flexibility for sponsors. These changes support Japan’s broader effort to improve access to pediatric medicines and reduce pediatric drug lag.
Reference